We then tested the therapeutic efficacy of dual drug therapy with celecoxib and orlistat since they are both ERS aggravators, have demonstrated preclinical efficacy against a variety of cancers, have mechanisms of action that would inhibit MUC2 protein expression/secretion, and target COX-2/FASN cancer pathways with significant crosstalk. The gene discussed is MUC2; the disease is cancer.